NEW YORK (GenomeWeb News) — Astellas Pharma will use MorphoSys’ HuCAL Gold antibody library in its drug-discovery efforts, MorphoSys said today.
Under the agreement, MorphoSys will receive an up-front payment and user fees over the course of the license, which may last up to five years.
MorphoSys said it could also receive research funding from preclinical and clinical development of compounds, as well as licensing, milestone, and royalty payments.
Astellas will use the HuCAL library at its facilities in Tsukuba, Japan, and has the option to start antibody projects over the span of the agreement, MorphoSys said.
The companies added a collaborative option into the agreement, under which MorphoSys would “generate novel HuCAL antibodies against targets provided by Astellas,” MorphoSys said.